IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases…
Category: Business
PanOptica Secures $11 Million to Advance Clinical Development of PAN-90806 – a Novel, Topical Anti-VEGF Eye Drop
BERNARDSVILLE, N.J.–(BUSINESS WIRE)–PanOptica announced that it has secured $11 million in a Series B financing. These funds will enable clinical advancement of PAN-90806.
Contact Lenses Market Analysis to 2025 by Product Type, Design Type, Usage Type – Research and Markets
DUBLIN–(BUSINESS WIRE)–The “Contact Lenses Market Analysis, by Product Type, by Design Type (Spherical, Toric, Multifocal), by Usage Type (Corrective, Therapeutic, Cosmetic, Prosthetic), by Regions and Segment Forecasts, 2014 – 2025” report has been …
OMEICOS Secures Extension of Series B Financing Round to Expand its Technology into Ophthalmology
BERLIN & BOSTON–(BUSINESS WIRE)–OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular diseases, today announced that it has secured an extension of its recently closed Series B financing round. The financing by US-based REMIGES Ventures will help to expand the development of OMEICOS’ technology into the field of ophthalmological disorders. The company’s novel technology is based o
GenSight Biologics to Attend Chardan Gene Therapy Conference
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that members of its management team will attend the following investor conference: Chardan Inaugural Gene Therapy ConferenceTuesday, October 10, 2017 – New York (USA)Thomas Gidoin, Chief Financia
Optometrist Reflects on Her Decade of Reading without the Need for Reading Glasses Thanks to the KAMRA® Corneal Inlay
IRVINE, Calif.–(BUSINESS WIRE)–#AcuFocus–Today marks Dr. Corina van de Pol’s 10-year anniversary with the KAMRA inlay, specifically designed for those with presbyopia.
Bio-Tissue Announces Strategic Agreement with Bright Optical to Promote its Regenerative Healing Technology in Canada
MIAMI & TORONTO–(BUSINESS WIRE)–Bio-Tissue, Inc., a business unit of TissueTech, Inc., is pleased to announce a strategic agreement with Bright Optical, a leading distributor of ophthalmic products in Canada, to help bring its PROKERA® biologic corneal bandage devices to the Canadian eye care professionals market. A significant part of this agreement and key milestone is that PROKERA has received Health Canada approval, which will help to provide greater patient access. “We are excited about
Simply Healthcare Plans Expands Reach of $0 Premium Medicare Advantage and Dual-Eligible Plans
MIAMI–(BUSINESS WIRE)–Simply Healthcare Plans (Simply) is expanding its $0 premium Medicare Advantage plans with six plans in three additional counties – Hernando, Palm Beach, and Pasco – for 2018, bringing the total to 11 counties where Simply will make plans available to Medicare-eligible Floridians. This expansion complements an already robust portfolio of health plans Simply offers in the state. All of these plans are available for enrollment in this year’s Medicare annual election period
Blue Cross and Blue Shield of Georgia Expands Reach of $0 Premium Medicare Advantage and Dual-Eligible Plans
ATLANTA–(BUSINESS WIRE)–Blue Cross and Blue Shield of Georgia (BCBSGa) is expanding its $0 premium Medicare Advantage plans with four plans in 16 additional counties for 2018, bringing the total to 43 counties where BCBSGa will make plans available to Medicare-eligible Georgians. This expansion complements an already robust portfolio of health plans BCBSGa offers in the state. All of these plans are available for enrollment in this year’s Medicare annual election period (AEP). The opportunity
Amerigroup Expands Reach of $0 Premium Medicare Advantage and Dual-Eligible Plans
NASHVILLE, Tenn.–(BUSINESS WIRE)–Amerigroup is offering its $0 premium Medicare Advantage plans in 92 counties to Medicare-eligible Tennesseans for 2018. This offering complements a robust portfolio of health plans Amerigroup offers in the state. All of these plans are available for enrollment in this year’s Medicare annual election period (AEP). The opportunity to enroll in a Medicare plan begins October 15 and continues through December 7. This is the one time each year when most people can
Samenvatting: German Ophthalmological Society (DOG) reikt dr. Uta Gehlsen prestigieuze wetenschapsprijs uit voor gebruik emigefluoreerd alkaan bij behandeling droge ogen
HEIDELBERG, Germany–(BUSINESS WIRE)–The German Ophthalmological Society (DOG) heeft dr. Uta Gehlsen van de Ocular Surface Group – onderdeel van de afdeling Oogheelkunde aan de Universiteit van Keulen – de “Dry Eye and Blepharitis/MGD Award” voor haar onderzoek naar het gebruik van semigefluoreerd alkaan (SFA F4H5) als nieuwe drager van ciclosporine A voor de topische behandeling van droge ogen. De DOG Awards brengen wetenschappelijke en academische excellentie onder de aandacht en stimuleren
Resumen: La German Ophthalmological Society (DOG) premia a Uta Gehlsen, PhD, con prestigioso reconocimiento por su investigación en el uso de alcanos semifluorados en el tratamiento del ojo seco
HEIDELBERG, Alemania–(BUSINESS WIRE)–La German Ophthalmological Society (DOG) ha entregado a Uta Gehlsen, PhD, del grupo de superficie ocular del departamento de oftalmología de la Universidad de Colonia, el premio “Dry Eye and Blepharitis/MGD” por su investigación en relación al uso de alcanos semifluorados (SFA F4H5) como nuevo portador de ciclosporina A para el tratamiento tópico de la enfermedad del ojo seco1. El comunicado en el idioma original, es la versión oficial y autorizada del mis
BioTime to Present at the Cell and Gene Meeting on the Mesa
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Jim Knight, SVP, Head of Corporate Development, will present at the Cell & Gene Therapy Meeting on the Mesa. Mr. Knight will provide an overview of the Company in his presentation on Thursday, October 5, 2017 at 4:45 pm PT/7:45 pm ET. About BioTime, Inc. BioTime is a late stage c
Die Deutsche Ophthalmologische Gesellschaft (DOG) ehrt Dr. Uta Gehlsen mit dem prestigeträchtigen Wissenschaftspreis für ihre Forschung zur Anwendung semifluorierter Alkane bei der Behandlung des trockenen Auges
HEIDELBERG, Deutschland–(BUSINESS WIRE)–Die Deutsche Ophthalmologische Gesellschaft (DOG) überreichte Dr. Uta Gehlsen, Arbeitsgruppe „Augenoberfläche“, Abteilung für Augenheilkunde, Universität Köln, für ihre Forschung zur Anwendung eines semifluorierten Alkans (SFA F4H5) als neuartiger Wirkstoffträger für Cyclosporin A zur topischen Behandlung des Syndroms des trockenen Auges (KCS) den Preis „Trockenes Auge und Blepharitis/MGD“.1 Die DOG ehrt wissenschaftliche und akademische Exzellenz und f
Anthem Blue Cross in California Offers Medicare Supplement Plan with Innovative Benefits to Help Members Control Health Care Costs
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Consumers in California with Original Medicare will be able to enroll in a Medicare Supplement Innovative Plan F from Anthem Blue Cross (Anthem), starting October 1, 2017. Anthem’s Innovative Plan F provides hearing and vision benefits as well as 24/7 nursing support via Nurse HelpLine. These benefits are in addition to those offered in a standard Plan F and may not be available with Plan Fs offered by other insurers. Anthem developed the Medicare Supplem
Riassunto: La Società oftalmologica tedesca (DOG) premia la signora Uta Gehlsen, PhD, con un prestigioso riconoscimento scientifico per la ricerca sull’uso degli alcani semifluorinati nel trattamento della secchezza oculare
HEIDELBERG, Germania–(BUSINESS WIRE)–La Società oftalmologica tedesca (DOG) (DOG) ha insignito Uta Gehlsen, PhD, del Gruppo superficie oculare del Dipartimento di oftalmologia dell’Università di Colonia, del premio “Dry Eye and Blepharitis/MGD” per la ricerca sull’uso di un alcano semifluorinato (SFA F4H5) come nuovo carrier per la ciclosporina A nel trattamento topico della secchezza oculare (DED).1 I riconoscimenti della Società oftalmologica tedesca premiano l’eccellenza scientifica e acca
Aerie Pharmaceuticals Announces Appointment of Ann Keevans as Director of Human Resources – Europe
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases…
Aerie Pharmaceuticals Announces Appointment of New Members of its Commercialization Team
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of David Biddell as Regional Sales Director for the Southeast Region, reporting to Gary Menichini, Aerie’s Vice President of Sales, and Shaun Gentry and Erin Horn, each as Director of National Accounts
Nightstar Announces Pricing of Initial Public Offering
LEXINGTON, Mass. & LONDON–(BUSINESS WIRE)–Nightstar Announces Pricing of Initial Public Offering
First Patient in the Nation Receives a Telescope Implant for Age-Related Macular Degeneration after Previous Cataract Surgery
SARATOGA, Calif.–(BUSINESS WIRE)–#AMD–First Patient in the Nation Receives a Telescope Implant for Age-Related Macular Degeneration after Previous Cataract Surgery